[{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGP-014","moa":"5-HT1A\/2A receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Biogaia Protectis","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus gasseri BGP345A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"BioGaia Pharma \/ BioFortis"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Gasseri DSM 27123","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus reuteri DSM17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"BioGaia Pharma \/ CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ CRC CHI Creteil France | Association Clinique Th\u00e9rapeutique Infantile du val de Marne | H\u00f4pital Universitaire Robert-Debr\u00e9"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus reuteri DSM17938","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oil","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Sprim CRO, Italia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri Protectis","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Sprim CRO, Italia","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Sprim CRO, Italia"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri Protectis DSM17938","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Vastra Gotaland Region","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Vastra Gotaland Region","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Vastra Gotaland Region"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Region Skane","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Region Skane","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Region Skane"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Jeffrey Pernica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"BioGaia Pharma \/ Jeffrey Pernica","highestDevelopmentStatusID":"11","companyTruncated":"BioGaia Pharma \/ Jeffrey Pernica"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Alexandra Papadopoulou","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ors Rehydration Solution","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"BioGaia Pharma \/ Alexandra Papadopoulou","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Alexandra Papadopoulou"}]

Find Clinical Drug Pipeline Developments & Deals by BioGaia Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Limosilactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          September 24, 2025

                          Lead Product(s) : Limosilactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          August 23, 2022

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus gasseri BGP345A is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Induced Constipation.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 24, 2021

                          Lead Product(s) : Lactobacillus gasseri BGP345A

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : BioFortis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : BGP-014 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colitis, Ulcerative.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 12, 2021

                          Lead Product(s) : BGP-014

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          October 08, 2020

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Biogaia Protectis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Dysbiosis.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          September 18, 2018

                          Lead Product(s) : Biogaia Protectis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          September 06, 2018

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Region Skane

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Urinary Tract Infections.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          December 08, 2017

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Lactobacillus reuteri DSM17938 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          April 10, 2017

                          Lead Product(s) : Lactobacillus reuteri DSM17938

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank